Efficacy of dupilumab and biomarkers for systemic corticosteroid naïve allergic bronchopulmonary mycosis

Allergol Int. 2021 Jan;70(1):145-147. doi: 10.1016/j.alit.2020.08.006. Epub 2020 Sep 8.

Authors

Hiroki Tashiro¹, Koichiro Takahashi², Yuki Kurihara², Hironori Sadamatsu², Shinya Kimura², Naoko Sueoka-Aragane²

Affiliations

¹ Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. Electronic address: si3222@cc.saga-u.ac.jp.
² Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.

PMID: 32917523
DOI: 10.1016/j.alit.2020.08.006

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adrenal Cortex Hormones
Aged
Antibodies, Fungal / blood
Antibodies, Monoclonal, Humanized / therapeutic use*
Aspergillosis, Allergic Bronchopulmonary / blood
Aspergillosis, Allergic Bronchopulmonary / diagnostic imaging
Aspergillosis, Allergic Bronchopulmonary / drug therapy*
Aspergillus / immunology
Biomarkers
Cytokines / antagonists & inhibitors
Cytokines / blood
Female
Humans
Immunoglobulin E / blood
Penicillium / immunology
Tomography, X-Ray Computed
Treatment Outcome

Substances

Adrenal Cortex Hormones
Antibodies, Fungal
Antibodies, Monoclonal, Humanized
Biomarkers
Cytokines
Immunoglobulin E
dupilumab